Tivdak improves survival

Seagen, Genmab’s Tivdak shows survival benefit in cervical cancer phase 3 trial

Amidst the Federal Trade Commission’s close scrutiny of Pfizer’s monumental $43 billion acquisition of Seagen, there’s a significant breakthrough in ...